title: Neuropeptide Y is an angiogenic factor in cardiovascular regeneration.
abstract: In diabetic cardiomyopathy, there is altered angiogenic signaling and increased oxidative stress. As a result, anti-angiogenic and pro-inflammatory pathways are activated. These disrupt cellular metabolism and cause fibrosis and apoptosis, leading to pathological remodeling. The autonomic nervous system and neurotransmitters play an important role in angiogenesis. Therapies that promote angiogenesis may be able to relieve the pathology in these disease states. Neuropeptide Y (NPY) is the most abundantly produced and expressed neuropeptide in the central and peripheral nervous systems in mammals and plays an important role in promoting angiogenesis and cardiomyocyte remodeling. It produces effects through G-protein-coupled Y receptors that are widely distributed and also present on the myocardium. Some of these receptors are also involved in diseased states of the heart. NPY has been implicated as a potent growth factor, causing cell proliferation in multiple systems while the NPY3-36 fragment is selective in stimulating angiogenesis and cardiomyocyte remodeling. Current research is focusing on developing a drug delivery mechanism for NPY to prolong therapy without having significant systemic consequences. This could be a promising innovation in the treatment of diabetic cardiomyopathy and ischemic heart disease.
authors.affiliation: Department of Surgery, Division of Cardiac Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
authors.forename: Rabya
authors.initials: R
authors.lastname: Saraf
authors.affiliation: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
authors.forename: Feroze
authors.initials: F
authors.lastname: Mahmood
authors.affiliation: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
authors.forename: Rabia
authors.initials: R
authors.lastname: Amir
authors.affiliation: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: rmatyal1@bidmc.harvard.edu.
authors.forename: Robina
authors.initials: R
authors.lastname: Matyal
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects*; D002319:Cardiovascular System / Q000187:drug effects*; D006801:Humans; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D017476:Receptors, Neuropeptide Y / Q000378:metabolism; D012038:Regeneration / Q000187:drug effects*
chemical_list: D043925:Angiogenesis Inducing Agents; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y
keywords: Angiogenesis; Cardiovascular regeneration; Diabetic cardiomyopathy; NPY(3-36); Neuropeptide Y